Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences
Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences
复制标题
DOI：
10.1002/ijc.24720
复制
发表时间：
2009-11-15
影响因子：
6.4
通讯作者：
Omata, Masao
中科院分区：
文献类型：
--
作者：
Nakagawa, Hayato;Maeda, Shin;Omata, Masao
白细胞介素-6（IL-6）可能在肝细胞癌（HCC）的发病机制中起一定作用。最近，据报道，在小鼠模型中，雌激素介导的IL-6产生的抑制解释了HCC中的性别差异。我们进行了一项回顾性队列研究，以检查这一假设是否适用于人类HCC。我们纳入了330例慢性丙型肝炎患者的血清样本收集于1994年1月至2002年12月。测定血清IL-6浓度，并根据IL-6水平将患者分为三组：低、中、高。我们评估了血清IL-6水平与随后HCC发展风险之间的关系，包括对每个性别的亚组分析。在随访期间（平均9.0年），126例患者发生HCC。三组间发病率差异有统计学意义（p = 0.015），发病率随血清IL-6水平升高而升高。然而，出乎意料的是，这种趋势仅在女性患者中显著。在多变量分析中，较高的血清IL-6水平是女性患者发生HCC的独立危险因素，风险比为1.61。虽然女性患者血清IL-6水平与雌二醇水平呈弱负相关，但女性患者HCC风险较低不能完全解释为雌激素介导的IL-6产生抑制。结论：血清IL-6水平升高是女性而非男性慢性丙型肝炎患者发生HCC的独立危险因素。血清IL-6水平的测量可能为预测女性慢性丙型肝炎患者未来的HCC发展提供有用的信息。(C)2009年UICC
Interleukin-6 (IL-6) may play a role in the pathogenesis of hepatocellular carcinoma (HCC). Recently, it was reported in mouse models that estrogen-mediated inhibition of IL-6 production explains the gender disparity in HCC. We conducted a retrospective cohort study to examine whether this hypothesis is applicable to human HCC. We enrolled 330 patients with chronic hepatitis C whose serum samples were collected between January 1994 and December 2002. Serum IL-6 concentrations were measured and patients were divided into three groups according to IL-6 levels: low, middle, and high. We evaluated the association between serum IL-6 levels and the risk of subsequent HCC development, including subgroup analysis on each gender. During the follow-up period (mean 9.0 yr),. HCC developed in 126 patients. The incidence dence rates differed significance among the three g groups (p = 0.015), increasing in accordance with serum IL-6 levels. However, unexpectedly, this tendency was significant only in female patients. In a multivariate analysis, higher serum IL-6 level was an independent risk factor for HCC development in female patients, with a hazard ratio of 1.61. Although female patients showed a weak negative correlation between serum IL-6 levels and estradiol levels, the lower risk of HCC in female patients cannot be fully explained by estrogen-mediated inhibition of IL-6 production. In conclusion, higher serum IL-6 level was an independent risk factor for HCC development in female but not male chronic hepatitis C patients. Measurement of serum IL-6 levels may provide useful information for predicting future HCC development in female chronic hepatitis C patients. (C) 2009 UICC